2010
DOI: 10.1002/cncr.24987
|View full text |Cite
|
Sign up to set email alerts
|

Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer

Abstract: BACKGROUND: This study examined the clinical significance of CCNE1 (Cyclin E1) amplification and assessed whether CCNE1 is a potential therapeutic target in ovarian cancer. METHODS: CCNE1 expression and amplification in ovarian cancer was assessed by immunohistochemistry, fluorescence in situ hybridization and clinical data collected by retrospective chart review. CCNE1 gene knockdown using silencing RNA and a CCNE1 gene transfection system were used to asses CCNE1 function in tissue samples of ovarian cancer.… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

21
139
1

Year Published

2012
2012
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 167 publications
(163 citation statements)
references
References 33 publications
21
139
1
Order By: Relevance
“…For example, in breast and ovarian cancers, in vitro silencing of CCNE1 suppresses cellular growth selectively in cells harboring CCNE1 amplification. 10,18,19 On the other hand, ectopic expression of CCNE1 increases cellular proliferation in ovarian cancer cell lines. 18 Moreover, these data support the driver role of CCNE1 amplification in cancers as cyclin E1 mediates G1/S transition through the activation of CDK2.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…For example, in breast and ovarian cancers, in vitro silencing of CCNE1 suppresses cellular growth selectively in cells harboring CCNE1 amplification. 10,18,19 On the other hand, ectopic expression of CCNE1 increases cellular proliferation in ovarian cancer cell lines. 18 Moreover, these data support the driver role of CCNE1 amplification in cancers as cyclin E1 mediates G1/S transition through the activation of CDK2.…”
Section: Discussionmentioning
confidence: 99%
“…10,18,19 On the other hand, ectopic expression of CCNE1 increases cellular proliferation in ovarian cancer cell lines. 18 Moreover, these data support the driver role of CCNE1 amplification in cancers as cyclin E1 mediates G1/S transition through the activation of CDK2. Interestingly, the survival of breast cancer cells harboring CCNE1 gene amplification depends on CDK2 expression and kinase activity.…”
Section: Discussionmentioning
confidence: 99%
“…The association between cyclin E amplification and poor outcome has also been identified in recent German and Japanese studies, although the correlation was not statistically significant in the latter (Mayr et al 2006, Nakayama et al 2010. Two independent labs have also suggested that amplification of the cyclin E gene was associated with primary treatment resistance and targeting cyclin E expression with siRNA reduced cell viability and increased apoptosis (Etemadmoghadam et al 2009, Nakayama et al 2010. These studies suggest that cyclin E amplification/expression may serve as both a prognostic and predictive factor in ovarian cancer as well as a therapeutic target in the treatment of ovarian cancer.…”
Section: Cell Cycle Regulatory Proteinsmentioning
confidence: 62%
“…Analysis of the subset of patients with serous carcinomas (72% of total study) showed an 11 month difference in median survival and suggested that the role of cyclin E was limited to the serous histology as nonserous tumors showed no statistically significant difference in survival based on cyclin E expression. The association between cyclin E amplification and poor outcome has also been identified in recent German and Japanese studies, although the correlation was not statistically significant in the latter (Mayr et al 2006, Nakayama et al 2010. Two independent labs have also suggested that amplification of the cyclin E gene was associated with primary treatment resistance and targeting cyclin E expression with siRNA reduced cell viability and increased apoptosis (Etemadmoghadam et al 2009, Nakayama et al 2010.…”
Section: Cell Cycle Regulatory Proteinsmentioning
confidence: 80%
See 1 more Smart Citation